You searched for "email"
Practice patterns of uveal melanoma management with Iodine-125 brachytherapy
With the 2006 Collaborative Ocular Melanoma Study Group (COMS) study demonstrating no difference in survival outcomes for participants randomised to either iodine-125 brachytherapy or enucleation, the majority of primary uveal melanomas in the United States are now treated with brachytherapy....
DRIL after macular oedema treatment in BRVO
The authors report the analysis of a single-site, retrospective, cross-sectional study to evaluate the association between disorganisation of the retinal inner layers (DRIL) and visual acuity (VA) after anti-VEGF treatment for macular oedema (MO) due to branch retinal vein occlusion...
Association between neurodegeneration and macular perfusion in the progression of diabetic retinopathy
In this prospective three-year longitudinal study, the authors aimed to explore the relation between retinal neurodegenerative changes and vessel closure (VC) in individuals with non-proliferative diabetic retinopathy (NPDR). The participants included 74 individuals with type 2 diabetes, NPDR, and Early...Charities to launch new sight loss councils in Scotland
Sight Scotland, Sight Scotland Veterans and Visibility Scotland are delighted to announce that, in partnership with the Thomas Pocklington Trust, they are launching new Sight Loss Councils in Scotland.
Outcomes of hemi DMEK
This was a prospective, interventional case series of 10 eyes from 10 patients who underwent hemi-descemet membrane endothelial keratoplasty (hemi-DMEK) for Fuchs endothelial dystrophy. The surgical technique for hemi DMEK procedure was similar to the circular DMEK except that a...
Risk of intraocular haemorrhage with new oral anticoagulants
The authors conducted a study to assess the risk of intraocular haemorrhage with warfarin dabigatran, rivaroxaban, apixaban. All reported cases of intraocular haemorrhage (vitreous, choroidal, or retinal) with warfarin and new oral anticoagulants (NOACs) (including dabigatran, rivaroxaban, apixaban) from the...
High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...
Intravitreal dexamethasone implant for recurrent CMO secondary to IGS
In this prospective study the authors present the data obtained on the efficacy and safety of the dexamethasone implant (0.7 mg) in the treatment of recurrent cystoid macular oedema (PCME) due to Irvine–Gass syndrome in patients with uncomplicated pseudophakia (off-label...
Review of non-arteritic anterior ischaemic optic neuropathy
This article reviews the risk factors, clinical presentation and therapies that have been investigated for non-arteritic anterior ischaemic optic neuropathy (NAAION). Additionally, it provides an update from recent rodent and primate models, offering a new insight into the pathophysiology of...
Intravitreal bevacizumab vs. ranibizumab in the treatment of macular oedema due to BRVO
This is a randomised, prospective, non-inferiority trial of 75 patients with macular oedema due to a branch retinal vein occlusion (BRVO) who received intravitreal injections of ranibizumab or bevacizumab after 1:1 block randomisation. This study is to measure the difference...
Retinal pigment epithelium tears
In this paper the authors review the current knowledge of retinal pigment epithelium (RPE) tears. Although rare these can cause loss of visual acuity. They can occur spontaneously in pigment epithelial detachment (PED) due to occult choroidal neovascularisation (CNV), retinal...
